Skip to content

Home / Knowledge hub / Beyond the contract: Driving transformational partnerships with manufacturing… and more

Beyond the contract: Driving transformational partnerships with manufacturing… and more

November 20, 2025

Achieving scientific breakthroughs is just one hurdle in today’s drug development and manufacturing process aimed at improving patient outcomes. Bringing a new therapy to market requires meticulous execution and clear communication at every step. Unfortunately, even the most groundbreaking scientific advancements can be delayed or even entirely abandoned due to poor performance from partners. This is why the quality of the relationship with a contract development and manufacturing organization (CDMO) really matters. A strong CDMO partnership can accelerate processes and ultimately deliver better outcomes for patients.

The team at Kindeva believes in going beyond the traditional transactional contract. We are committed to transforming the CDMO-client relationship into a true partnership built on consistency, transparency and trust, all designed for long-term success.

In this blog post, we explore how Kindeva’s customer-first mindset, subject matter expert (SME)-led model and capabilities work together to deliver measurable outcomes, mitigate risks and help our partners bring life-changing therapies to patients who need them.


Why customer experience matters


In recent years, the role of CDMOs has profoundly changed. What once were primarily transactional service providers focused on execution have evolved into indispensable strategic partners. Today’s pharmaceutical and biotech clients demand more than just technical capability: they seek foresight, seamless integration and a partner as invested in their program’s success as they are. This significant shift is being shaped by market forces and increasingly complex program demands:

  • Increasing therapeutic complexity
    Modern therapies are becoming increasingly complex and specialized. This requires a deeper level of technical alignment and more robust risk management strategies throughout every stage of the development process.
  • Greater market volatility
    In a dynamic market, launch success is no longer guaranteed by technical expertise alone. It also hinges on adaptability, strong integration across various functions and the ability of a partner to anticipate and effectively manage change.
  • Rising customer expectations
    Clients are now actively seeking CDMOs that can offer strategic input, ensure clear and consistent communication, and provide the flexibility to scale operations in alignment with their evolving needs.

In this environment, customer experience has become not just a preference, but an essential element for building truly impactful partnerships that deliver.

At the core of Kindeva’s distinctive approach is an unwavering commitment to consistency, flexibility and diligent follow-through. Our SME-led model is designed to build deep alignment between our internal teams and our clients, promoting trust and significantly reducing the potential for missteps or unnecessary handoffs. We believe in embedding our teams early in the process, listening actively to understand each client’s unique needs and adapting fluidly to their specific program goals and culture. This collaborative approach helps create a solid foundation for a lasting, productive partnership from the outset, which in turn shapes every subsequent action: how we plan, how we communicate and how we drive each program forward with a shared focus and accountability.

 

A customer-centric approach in action


At Kindeva, our approach is to become an extension of each client’s team. This means aligning with their unique culture, specific program goals and inherent risk profile. Our approach is proactive and collaborative, beginning with the early integration of multidisciplinary teams into the development process. This early integration is crucial, as it enables us to establish strong alignment from the outset and anticipate potential challenges before they materialize.

Our experts operate as one integrated team across development, device, regulatory and manufacturing. This creates a powerful dynamic that consistently reduces risk throughout the entire development process, streamlining timelines. Kindeva is uniquely positioned to help partners with programs from initial concept through to commercialization.

This customer-centric philosophy is supported by a set of core values that guide every interaction and decision. We call these our PRECISE values:

  • Personal responsibility
  • Respect
  • Energy
  • Communication
  • Innovation
  • Service
  • Excellence

These values are the driving principles that define how Kindeva engages with clients, manages projects and ensures shared success.


Delivering value beyond manufacturing


As we have explored, the journey of drug development and manufacturing today demands a shift from traditional transactional relationships to truly transformative partnerships. Kindeva’s commitment to going beyond the contract is evident in every aspect of our operations, from our proactive customer-centric philosophy to our cutting-edge capabilities.

We have seen how our PRECISE values and SME-led model promote alignment, consistent communication and a shared sense of accountability, significantly reducing friction and accelerating progress.

Ultimately, Kindeva’s approach is about more than just manufacturing — it’s about building enduring partnerships that deliver exceptional value. By unifying core functions, embracing innovation and consistently putting the client and patient first, we empower our partners to navigate complexity with confidence. This strategy enables faster time to market, enhanced compliance and, most importantly, better outcomes for patients worldwide. Together, we are building the better tomorrows that the healthcare landscape urgently needs.


Ready to learn how a strategic CDMO partnership can revolutionize your drug development and manufacturing initiatives?

Download our recent eBook on the Kindeva customer experience to explore our comprehensive approach and discover how we can help you manufacture more tomorrows.

Download here.

Related resources

Explore our other resources to discover valuable insights on the latest trends in drug delivery.

Why Kindeva: Analytical and regulatory services

Overcome complex analytical and regulatory challenges with a partner dedicated to your product’s success. Our specialist expertise helps you navigate testing, compliance, and quality to advance your project from concept to commercialization. Download our one-pager for a closer look at our integrated approach, including: An overview of our comprehensive, phase-appropriate analytical services. How our regulatory […]

Learn More

Career journeys blog 2: Oliver Ingham

In this latest installment, we meet Oliver Ingham, an analytical chemist whose curiosity and problem-solving skills have shaped his journey from academic research to coordinating analytical development services at Kindeva.

Learn More

Career journeys blog 1: Holly Dowdle

When Holly Dowdle first joined Kindeva as a student intern, she experienced a workplace that valued both curiosity and collaboration. It was an environment where asking questions was encouraged and development was part of everyday work, not something that happened on the sidelines.

Learn More

A bridge between design and delivery: Exploring sterile fill finish integration for injectable product success

The global sterile injectable contract manufacturing market is experiencing rapid growth, driven by increasing demand for advanced biologics, glucagon-like peptide-1 (GLP-1) therapies and other injectables. These products pair drugs with delivery devices to support patient-centric care, but their manufacturing presents unique challenges. Programs often require specialized environments, such as cold-chain storage and low-volume fills, and […]

Learn More

Going beyond manufacturing: The Kindeva customer experience

Going beyond manufacturing: The Kindeva customer experience As development timelines tighten and product complexity grows, the quality of CDMO partnerships has transformed into a critical success factor. In today’s high-stakes landscape, drug developers need more than technical execution. They need partners who embed early, stay aligned and help navigate every phase of the product lifecycle. […]

Learn More

Built for better tomorrows: How Bridgeton delivers for patients

Kindeva’s Bridgeton facility offers a purpose-built solution for the complex and evolving landscape of injectable drugs. The facility was specifically designed to address challenges in sterile injectable manufacturing, such as the siloed approaches that often separate core functions like formulation and fill finish. By co-locating these functions and operating within integrated systems, the Bridgeton model […]

Learn More

Building confidence into complex drug-device programs with early analytical expertise

Drug-device programs are under pressure to do more, with tighter timelines, deeper scrutiny and increasing complexity.  As teams move from concept through clinical and commercial phases, one challenge remains constant: ensuring products behave as intended, consistently and safely. That challenge gets more complicated as formulation, device mechanics, packaging and regulatory expectations converge. Whether developing an […]

Learn More

What makes Bridgeton the perfect partner for your next sterile fill finish project?

The pharmaceutical sector is experiencing a significant increase in the demand for advanced biologics, biosimilar therapies and other sterile injectables. As a result, the global sterile injectables market is projected to grow from $632 billion in 2025 to $1.078 trillion by 2032, with a compound annual growth rate of 7.9% [1]. In response to this […]

Learn More

From vial to value: How GLP-1s are redefining injectable care for chronic conditions

The market for glucagon-like peptide-1 (GLP-1) therapies is growing rapidly, with a projected value of $186.6 billion by 2032. Originally developed for diabetes, these therapies are now widely used for obesity treatment, which has created a need for convenient and scalable delivery systems. This growth is reshaping the industry, creating new demands on manufacturing capacity […]

Learn More

Let’s transform tomorrow together

Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.